Affiliations 

  • 1 National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
  • 2 International Agency for Research on Cancer (IARC-WHO), Lyon, France
  • 3 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway
  • 4 Department of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
  • 5 Department of Epidemiology, Rollins School of Public Health, Winship Cancer Institute, Emory University, Atlanta, GA
  • 6 Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
  • 7 Division of Human Nutrition, Wageningen University & Research, Wageningen, The Netherlands
  • 8 Department of Clinical Chemistry, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
  • 9 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
  • 10 Danish Cancer Society Research Center, Copenhagen, Denmark
  • 11 Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus C, Denmark
  • 12 Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
  • 13 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 14 Department of Epidemiology, German Institute for Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
  • 15 Hellenic Health Foundation, Athens, Greece
  • 16 Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy
  • 17 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  • 18 Cancer Registry and Histopathology Unit, "Civic - M.P.Arezzo" Hospital, ASP Ragusa, (Italy)
  • 19 Dipartimento di medicina clinica e chirurgia, Federico II university, Naples, Italy
  • 20 Department of Medical Sciences, University of Torino, Torino, Italy
  • 21 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
  • 22 Oviedo University, Asturias, Spain
  • 23 Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
  • 24 Public Health Direction and Biodonostia-Ciberesp, Basque Regional Health Department, San Sebastian, Spain
  • 25 CIBER de Epidemiología y Salud Pública (CIBERESP), Spain
  • 26 Department of Surgery, Lund University, Skåne University Hospital Malmö, Malmö, Sweden
  • 27 Department of Surgery, Endocrine-Sarcoma unit, Skane University Hospital, Lund, Sweden
  • 28 Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden
  • 29 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • 30 MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
  • 31 University of Cambridge, Cambridge, United Kingdom
  • 32 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • 33 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom
Int J Cancer, 2018 Mar 15;142(6):1189-1201.
PMID: 29114875 DOI: 10.1002/ijc.31146

Abstract

Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer (PC). However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and PC incidence in European populations. We conducted a pooled nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study's second survey (HUNT2) cohorts. In total, 738 primary incident PC cases (EPIC n = 626; HUNT2 n = 112; median follow-up = 6.9 years) were matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smoking habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). Compared with a reference category of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42-1.20); 0.94 (0.72-1.22); 1.12 (0.82-1.53) and 1.26 (0.79-2.01) for clinically pre-defined categories of ≤25; >25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with PC risk (p for trend = 0.23). Although these findings among participants from the largest combination of European cohort studies to date show increasing effect estimates of PC risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.